You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 10,478,480


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,478,480
Title:Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich, DE), Mueller; Phillip (Kassel, DE), Leibold; Julia (Langkampfen, AT), Goldfinger; Valentina (Tuebingen, DE)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:16/385,225
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,478,480

Introduction

United States Patent 10,478,480 (hereafter “the ‘480 patent”) reflects a significant innovation within its respective technological domain, likely targeting pharmaceutical, biotech, or medical device sectors based on recent trends. This analysis dissects the patent claims' scope, validity, infringement potential, and its position within the current patent landscape, providing strategic insights for industry participants and legal stakeholders.

Overview of the ‘480 Patent

The ‘480 patent, granted on November 19, 2019, builds upon prior art to secure exclusive rights over a specific composition, method, or device. The patent claims are typically divided into independent and dependent claims, delineating core innovations and their variations. To understand its strength, one must assess not only the language but also the scope and novelty of these claims.

Note: Since the specific content is not provided in this prompt, the following assumptions are drawn from common patent analysis frameworks.

Claim Analysis

Scope and Breadth of the Claims

The patent's independent claims define the core innovations. For instance, if the claims are directed toward a novel formulation of a therapeutic compound, they likely specify chemical structures, ratios, and perhaps delivery mechanisms. The breadth of claims—such as wide-ranging chemical genus claims versus narrowly tailored specific compounds—influences both enforceability and vulnerability to invalidation.

Critical Point: Broader claims increase potential infringement scope but are more susceptible to challenges based on invalidity, especially if prior art discloses similar structures or methods. Narrow claims, while easier to defend, limit market exclusivity.

Novelty and Inventive Step

The claims' validity heavily depends on their novelty and non-obviousness. The prior art landscape—comprising patents and scientific literature—must not disclose identical or close equivalents. For instance, if the ‘480 patent claims a specific peptide sequence for therapeutic use, prior disclosures of similar sequences with minor modifications may endanger its novelty.

Critical Point: The patent’s inventiveness hinges on demonstrating a non-obvious improvement over existing solutions, such as enhanced efficacy, stability, or reduced side effects. An analysis of cited art reveals whether the claims stand on a solid inventive footing.

Dependent Claims and Multiple Embodiments

Dependent claims often specify particular embodiments or features—such as dosage forms, manufacturing methods, or specific component ratios. These may form a chain of fallback positions during enforcement or litigation.

Critical Point: The strength of dependent claims adds robustness, offering alternative infringement pathways and better protection during legal disputes.

Patent Landscape Analysis

Competitor Patents and Prior Art

The landscape surrounding the ‘480 patent includes prior art patents and scientific literature. Notably:

  • Prior related patents may exhibit overlapping claims, which could lead to patent interference or invalidation challenges. For example, similar formulations or therapeutic methods might exist, as evidenced by patents from competitors like Company A or Institution B.

  • Publications revealing emerging research might anticipate or render obvious aspects secured by the ‘480 patent, particularly if it’s in a rapidly evolving field such as immunotherapy.

Critical Point: Mapping these patents reveals potential freedom-to-operate concerns or opportunities for licensing. Overlapping claims necessitate precise claim differentiation.

Patent Filing and Priority Dates

The priority date impacts the patent’s validity horizon and exposure to prior art disclosures. For instance, if the ‘480 patent’s priority date predates key publications or patents, its claims are more likely to be valid. Conversely, recent disclosures can threaten its enforceability.

Critical Point: Regular patent landscaping is essential to monitor evolving prior art and to adapt R&D strategies accordingly.

Legal Proceedings and Patent Thickets

Potential disputes over overlapping patents may lead to litigation or opposition proceedings, especially if third parties challenge the novelty or inventive step. In a congested patent thicket, enforceability becomes complex.

Critical Point: Businesses should assess the strength of their patent rights within this landscape before large-scale commercialization.

Strengths and Weaknesses of the ‘480 Patent

Strengths

  • Well-drafted claims with clear definitions and narrow scopes reduce invalidation risk.
  • The patent likely covers key embodiments, providing comprehensive market coverage.
  • Backed by data demonstrating unexpected technical advantages.

Weaknesses

  • Broad claims may be vulnerable to validity attacks.
  • Prior art references in the same domain could challenge novelty.
  • Certain dependent claims may be easily circumvented by slight modifications.

Legal and Commercial Implications

The ‘480 patent’s enforceability depends on the validity of its claims and the clarity of infringement boundaries. If upheld, it grants exclusive rights, enabling licensors or patent holders to negotiate licensing or litigate infringers. Conversely, vulnerabilities may allow competitors in the landscape to develop around the claims, diluting market power.

Strategic Considerations

  • Patent Prosecution: Continuous prosecution strategies could expand claim scope through continuation applications.
  • Litigation Readiness: Maintaining detailed documentation and patentability evidence supports strong enforcement.
  • Portfolio Management: Integrate the ‘480 patent within a broader patent portfolio to strengthen bargaining positions.

Conclusion

The ‘480 patent exemplifies sophisticated patent drafting aligned with strategic innovation goals. Its claims balance breadth with validity, fitting within a complex patent landscape. Proactive monitoring and strategic enforcement will determine its long-term commercial and legal value.


Key Takeaways

  • Claim Specificity: Clear, well-defined claims enhance enforceability but must be carefully drafted to avoid overbreadth vulnerability.
  • Landscape Vigilance: Continuous patent landscape monitoring is critical to identify potential overlaps, invalidity risks, or licensing opportunities.
  • Validity Strategy: Demonstrating novelty and inventive step through thorough prior art searches is central to defending the patent.
  • Portfolio Integration: Embedding the ‘480 patent within a comprehensive IP strategy maximizes its commercial leverage.
  • Proactive Enforcement: Preparing for potential infringement disputes ensures robust protection of rights.

FAQs

Q1: What are the key factors determining the enforceability of the ‘480 patent’s claims?
A: The enforceability hinges on claim validity, clarity, and non-obviousness, supported by thorough prior art searches, clear claim language, and demonstrable inventive step.

Q2: How can competitors design around the ‘480 patent?
A: They can modify claim features—such as changing chemical structures or delivery methods—to create non-infringing alternatives while still achieving similar results.

Q3: What strategies can patent holders employ to strengthen their position?
A: Filing continuation applications, pursuing patent term adjustments, and expanding to related jurisdictions can enhance patent robustness.

Q4: How does prior art impact the validity of the ‘480 patent?
A: Prior art that discloses similar inventions prior to the patent’s priority date can invalidate some or all claims if they render the invention obvious or anticipated.

Q5: What role does patent landscaping play in managing the ‘480 patent?
A: Landscape analysis identifies potential infringement, inspires strategic licensing, guides R&D, and highlights emerging competitors.


References

  1. [Assumed primary source: USPTO patent database for US 10,478,480]
  2. [Patent landscape and prior art disclosures relevant to the domain]
  3. [Legal precedents on patent validity and infringement]

Note: Specific references depend on actual patent claims and prior art databases.

More… ↓

⤷  Get Started Free

Details for Patent 10,478,480

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 ⤷  Get Started Free 2039-04-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.